ES2293247T3 - Polipeptidos quimericos y su utilizacion. - Google Patents

Polipeptidos quimericos y su utilizacion. Download PDF

Info

Publication number
ES2293247T3
ES2293247T3 ES04727873T ES04727873T ES2293247T3 ES 2293247 T3 ES2293247 T3 ES 2293247T3 ES 04727873 T ES04727873 T ES 04727873T ES 04727873 T ES04727873 T ES 04727873T ES 2293247 T3 ES2293247 T3 ES 2293247T3
Authority
ES
Spain
Prior art keywords
cells
dna
polypeptide
cell
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04727873T
Other languages
English (en)
Spanish (es)
Inventor
Christian Kuhne
Andras Simoncsits
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ICGEB
International Centre for Genetic Engineering and Biotechnology
Original Assignee
ICGEB
International Centre for Genetic Engineering and Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ICGEB, International Centre for Genetic Engineering and Biotechnology filed Critical ICGEB
Application granted granted Critical
Publication of ES2293247T3 publication Critical patent/ES2293247T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21004—Type II site-specific deoxyribonuclease (3.1.21.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
ES04727873T 2003-04-18 2004-04-16 Polipeptidos quimericos y su utilizacion. Expired - Lifetime ES2293247T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000821A ITMI20030821A1 (it) 2003-04-18 2003-04-18 Polipeptidi chimerici e loro uso.
ITMI03A0821 2003-04-18

Publications (1)

Publication Number Publication Date
ES2293247T3 true ES2293247T3 (es) 2008-03-16

Family

ID=33187374

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04727873T Expired - Lifetime ES2293247T3 (es) 2003-04-18 2004-04-16 Polipeptidos quimericos y su utilizacion.

Country Status (16)

Country Link
US (3) US20060292629A1 (https=)
EP (1) EP1616011B1 (https=)
JP (2) JP4794432B2 (https=)
KR (2) KR101360781B1 (https=)
CN (1) CN100584950C (https=)
AT (1) ATE374826T1 (https=)
AU (1) AU2004230254B2 (https=)
CA (1) CA2522525A1 (https=)
CY (1) CY1107115T1 (https=)
DE (1) DE602004009301T2 (https=)
DK (1) DK1616011T3 (https=)
ES (1) ES2293247T3 (https=)
IT (1) ITMI20030821A1 (https=)
PL (1) PL1616011T3 (https=)
PT (1) PT1616011E (https=)
WO (1) WO2004092194A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.
NL1027479C2 (nl) * 2004-10-21 2006-05-01 Synvolux Ip B V Bescherming van biologisch actieve moleculen met behulp van amphifielen.
MX2007010073A (es) * 2005-02-18 2007-10-10 Astrazeneca Ab Metodo para determinar la respuesta de los inhibidores de chk1.
GB0609119D0 (en) * 2006-05-09 2006-06-21 Univ Birmingham Histones
WO2008141096A2 (en) * 2007-05-11 2008-11-20 The Regents Of The University Of California Nucleic acids for inducing expression of transcripts and proteins and methods for making and using them
HK1231556A1 (zh) 2014-02-17 2017-12-22 克劳德贝尔纳里昂第一大学 确定组织放射敏感性的预测方法
CN104193826B (zh) * 2014-09-17 2018-02-23 山东大学齐鲁医院 一种融合多肽及其在制备抗肿瘤药物中的应用
WO2017178885A2 (en) * 2016-04-12 2017-10-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methylmalonyl coenzyme a mutase (mcm) fusion constructs for the treatment of disorders associated with mcm deficiency
JP6925003B2 (ja) * 2016-05-10 2021-08-25 公立大学法人横浜市立大学 非相同末端連結欠損細胞及びその利用
AU2017271678B2 (en) * 2016-05-27 2021-05-06 Synthex, Inc. Protein interfaces
EP3469070B1 (en) * 2016-06-09 2021-08-04 Alma Mater Studiorum - Università di Bologna Herpesvirus with modified glycoprotein b
WO2018232356A1 (en) 2017-06-15 2018-12-20 The Regents Of The University Of California Targeted non-viral dna insertions
JP7101419B2 (ja) 2017-10-27 2022-07-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 内因性ｔ細胞受容体の標的置換
GB2584210B (en) 2017-11-22 2022-03-16 Synthex Inc Peptides for inhibiting RAD51
JP2024537991A (ja) 2021-10-14 2024-10-18 アーセナル バイオサイエンシズ インコーポレイテッド 共発現されるｓｈＲＮＡと論理ゲートシステムとを有する免疫細胞
WO2023111213A1 (en) 2021-12-16 2023-06-22 Rdp Pharma Ag Cell penetrating polypeptides (cpps) and their use in human therapy
CN116023512A (zh) * 2023-02-16 2023-04-28 浙江大学 一条靶向dna损伤修复蛋白的多肽及其用途
EP4480497A1 (en) 2023-06-21 2024-12-25 RDP Pharma AG Bio-conjugates for oncology

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
CA2361191A1 (en) * 1999-02-03 2000-08-10 The Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
EP1165819A2 (en) * 1999-03-31 2002-01-02 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
WO2001074905A1 (en) * 2000-04-03 2001-10-11 Antisoma Research Limited Compounds for targeting
GB0112818D0 (en) * 2001-05-25 2001-07-18 Lorantis Ltd Conjugate
EP1342781A1 (en) * 2002-03-09 2003-09-10 ARTEMIS Pharmaceuticals GmbH Recombinase fusion protein with enhanced cellular uptake
EP2806025B1 (en) * 2002-09-05 2019-04-03 California Institute of Technology Use of zinc finger nucleases to stimulate gene targeting
ITMI20030821A1 (it) * 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And Polipeptidi chimerici e loro uso.

Also Published As

Publication number Publication date
JP2011182792A (ja) 2011-09-22
WO2004092194A2 (en) 2004-10-28
CY1107115T1 (el) 2012-01-25
DE602004009301D1 (de) 2007-11-15
JP4794432B2 (ja) 2011-10-19
CA2522525A1 (en) 2004-10-28
KR20060003029A (ko) 2006-01-09
CN1768142A (zh) 2006-05-03
CN100584950C (zh) 2010-01-27
PL1616011T3 (pl) 2008-05-30
PT1616011E (pt) 2008-01-07
US20150018409A1 (en) 2015-01-15
KR20110074948A (ko) 2011-07-04
KR101360781B1 (ko) 2014-04-24
EP1616011A2 (en) 2006-01-18
AU2004230254A1 (en) 2004-10-28
DK1616011T3 (da) 2008-02-04
DE602004009301T2 (de) 2008-07-17
US20060292629A1 (en) 2006-12-28
EP1616011B1 (en) 2007-10-03
ITMI20030821A1 (it) 2004-10-19
WO2004092194A3 (en) 2005-03-17
JP2006523448A (ja) 2006-10-19
AU2004230254B2 (en) 2008-10-02
US20110033384A1 (en) 2011-02-10
ATE374826T1 (de) 2007-10-15
KR101247704B1 (ko) 2013-03-26

Similar Documents

Publication Publication Date Title
ES2293247T3 (es) Polipeptidos quimericos y su utilizacion.
Syed et al. The MRE11–RAD50–NBS1 complex conducts the orchestration of damage signaling and outcomes to stress in DNA replication and repair
Balmus et al. ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks
Rupnik et al. MRN and the race to the break
Williams et al. Mre11–Rad50–Nbs1 is a keystone complex connecting DNA repair machinery, double-strand break signaling, and the chromatin template
Siaud et al. Plasticity of BRCA2 function in homologous recombination: genetic interactions of the PALB2 and DNA binding domains
WO1996012820A1 (en) INTERACTIONS BETWEEN Raf PROTO-ONCOGENES AND CDC25 PHOSPHATASES, AND USES RELATED THERETO
García Fernández et al. Global chromatin mobility induced by a DSB is dictated by chromosomal conformation and defines the HR outcome
Marlaire et al. Bartonella effector protein C mediates actin stress fiber formation via recruitment of GEF-H1 to the plasma membrane
Rauh et al. MS-based in situ proteomics reveals AMPylation of host proteins during bacterial infection
Roy et al. DNA-binding properties of Smc6, a core component of the Smc5–6 DNA repair complex
Popova et al. Posttranslational modifications of Rad51 protein and its direct partners: Role and effect on homologous recombination–mediated DNA repair
Stolworthy et al. A novel Escherichia coli strain allows functional analysis of guanylate kinase drug resistance and sensitivity
Filipovic Phage display to identify functional resistance mutations to Rigosertib
Elia Proteomic screen reveals that the Polo-box domain is a phosphoserine/threonine-binding module
Kulepa Probing interactions of the BRCT protein family with damaged chromatin
Hossain APE2 Is a Critical Regulator of the DNA Damage Response to Maintain Genome Integrity in Mammalian Cells
Vellalore Maruthachalam Lariat peptide inhibitors of Abl kinase
Wu Roles of NBS1 and BRCA2 cancer susceptibility genes in the maintenance of genome stability
Rettich Characterisation of the DNA endonuclease subunit EME1 as novel substrate of sumoylated Ubc9
Lerksuthirat et al. Development of biosensor-based DNA repair pathway for high-throughput screening technology by using DT40 cell line as the model
McKerlie Functional Analysis of TRF1 Phosphorylation in Telomere Maintenance, Cell Cycle Regulation, and the DNA Damage Response
Maity PHILOSOPHIAE DOCTOR (PH. D.)
Udayakumar Identification and characterization of two new players in DNA double-strand break repair: PSF and p54 (nrb)
Paquin Characterization of a H4K20me2 methyl-binding domain in the Fanconi anemia protein FANCD2